THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Disease & Clinical Pharmacy Guides • 3-TIER LEARNING GUIDE

Essential Hypertension: Pathophysiology, I-GH-IV / ESC Thresholds & Combination Therapy

Editorial Body: Tejas Nartam Reading Time: 9 min read Published: 2026-01-15 Last Updated: 2026-11-08 Status: Evidence-Sourced Educational Guide

1. Level 1 — Quick Learning Overview & Core Definition

Quick Concept Summary: Essential hypertension is defined under the Indian Guidelines on Hypertension (I-GH-IV) as persistent office blood pressure >= 140/90 mmHg. First-line antihypertensive pharmacotherapy comprises ACE inhibitors (Ramipril, Enalapril), Angiotensin Receptor Blockers (Telmisartan, Losartan), Dihydropyridine Calcium Channel Blockers (Amlodipine, Cilnidipine), and Thiazide/Thiazide-like Diuretics (Chlorthalidone, Indapamide, Hydrochlorothiazide).

2. Level 2 — Standard Study: Underlying Process & Major Classifications

Arterial blood pressure equals Cardiac Output multiplied by Systemic Vascular Resistance (BP = CO x SVR). Dysregulation of the Renin-Angiotensin-Aldosterone System (RAAS), sympathetic nervous system overactivity, endothelial nitric oxide deficiency, and renal sodium retention drive chronic vascular remodelling and target-organ damage (left ventricular hypertrophy, hypertensive nephropathy, stroke, and retinopathy).

Major Pharmacological & Scientific Classifications

  • ACE Inhibitors (Enalapril, Ramipril, Perindopril): Inhibit conversion of Angiotensin I to Angiotensin II and block bradykinin breakdown; first-line in diabetes with proteinuria and HFrEF.
  • Angiotensin II Receptor Blockers (Telmisartan, Losartan, Olmesartan): Selectively block AT1 receptors without bradykinin accumulation (markedly lower incidence of dry cough).
  • Dihydropyridine CCBs (Amlodipine, Cilnidipine, Nifedipine SR): Block vascular smooth muscle L-type Cav1.2 channels; effective across all age groups and isolated systolic hypertension.
  • Thiazide & Thiazide-Like Diuretics (Chlorthalidone, Indapamide, HCTZ): Inhibit distal convoluted tubule Na+/Cl- cotransport (NCC).
  • Drugs of Choice in Pregnancy: Oral Labetalol, Nifedipine Extended-Release, and Alpha-Methyldopa (ACEi and ARBs are strictly contraindicated due to fetotoxicity).

3. Original Scientific Illustration (PLATE-8.10: 8.10 Antihypertensive Pharmacology: RAAS Cascade, Bradykinin Pathway, CCBs, Diuretics & Sympatholytics)

ANTIHYPERTENSIVE PHARMACOLOGY: RAAS CASCADE, CALCIUM CHANNELS & NEPHRON SITES RENIN–ANGIOTENSIN–ALDOSTERONE SYSTEM (RAAS) 1. Juxtaglomerular Renin Release ← [Blocked by β1-Blockers: Metoprolol, Bisoprolol] 2. Angiotensinogen (Liver) → Angiotensin I (Decapeptide) 3. ACE Inhibitors (Ramipril, Enalapril, Perindopril) Block ACE: • Prevents Angiotensin I → Angiotensin II (↓ Vasoconstriction & ↓ Aldosterone) • Prevents Bradykinin breakdown (↑ NO/PGI2 vasodilation; Dry Cough ADR) 4. Angiotensin Receptor Blockers — ARBs (Telmisartan, Losartan, Olmesartan): • Selectively block AT1 Receptor (Gq) → Vasodilation & Efferent arteriole dilation • Does NOT inhibit bradykinin degradation (Minimal cough) 5. Mineralocorticoid Antagonists (Spironolactone, Eplerenone): Block Aldosterone Contraindicated in Pregnancy (ACEi/ARB Fetotoxicity) & Bilateral Renal Artery Stenosis Never combine ACEi + ARB (ONTARGET Trial: ↑ Hyperkalaemia & AKI) VASCULAR CALCIUM CHANNELS & DIURETIC TARGETS Dihydropyridine CCBs (Amlodipine, Cilnidipine, Nifedipine): • Block vascular smooth muscle L-type Ca2+ channels (Cav1.2) → Arterial dilation • Cilnidipine also blocks sympathetic N-type Ca2+ channels (↓ pedal oedema) Non-Dihydropyridine CCBs (Verapamil, Diltiazem): • Block SA/AV nodal & myocardial Ca2+ channels (↓ HR, ↓ AV conduction) • Avoid combining Verapamil/Diltiazem with Beta-Blockers (Heart block risk) Thiazide & Thiazide-Like Diuretics (Chlorthalidone, Indapamide, HCTZ): • Inhibit Na+/Cl- cotransporter (NCC) in Distal Convoluted Tubule • Monitor Electrolytes: Hypokalaemia, Hyponatraemia, Hyperuricaemia Central Sympatholytics & Pregnancy Hypertension: • First-line in Pregnancy: Labetalol (α1/β-blocker), Nifedipine SR, Methyldopa (α2-agonist)
Figure 8.10: Integrated cardiovascular site-of-action map for antihypertensive drug classes: ACE Inhibitors, ARBs, Dihydropyridine vs Non-Dihydropyridine CCBs, Thiazide/Loop/K+-Sparing Diuretics, and Beta-Blockers.
Diagram Walkthrough: Blood pressure is regulated by Cardiac Output (Heart Rate × Stroke Volume) and Systemic Vascular Resistance (SVR). (1) Renin-Angiotensin-Aldosterone System (RAAS): Juxtaglomerular cells secrete Renin (stimulated by beta-1 adrenoceptors and low renal perfusion), converting hepatic Angiotensinogen to Angiotensin I. Angiotensin-Converting Enzyme (ACE) converts Angiotensin I to Angiotensin II and simultaneously degrades vasodilatory Bradykinin. ACE Inhibitors (Ramipril, Enalapril) block both pathways — lowering Angiotensin II-mediated vasoconstriction and aldosterone secretion while elevating bradykinin (which contributes to vasodilation but can cause dry cough or angioedema). ARBs (Telmisartan, Losartan) selectively block the AT1 receptor without elevating bradykinin. (2) Calcium Channel Blockers: Dihydropyridines (Amlodipine, Cilnidipine) selectively block vascular smooth muscle L-type Cav1.2 channels, reducing SVR. (3) Thiazide/Thiazide-like Diuretics (Chlorthalidone, Indapamide, HCTZ) inhibit distal convoluted tubule Na+/Cl- cotransporter (NCC). Combining an ACEi and an ARB is contraindicated due to hyperkalaemia and acute kidney injury.

4. Level 3 — Advanced Clinical, Pharmacokinetic & Regulatory Reference

Combination Therapy & Haemodynamic Safeguards: For Stage 2 hypertension (>= 160/100 mmHg), single-pill fixed-dose combinations (such as Telmisartan + Amlodipine or Telmisartan + Chlorthalidone) improve adherence and achieve faster blood pressure control through complementary mechanisms (RAAS blockade attenuates CCB-induced reflex sympathetic activation and ankle oedema by dilating post-capillary venules). Never combine an ACE inhibitor with an ARB (dual RAAS blockade increases hyperkalaemia, hypotension, and acute kidney injury without mortality benefit).

5. Common Misunderstandings & Clinical Pitfalls

Common Misunderstanding: Discontinuing an ACEi or ARB immediately upon a minor (< 25%–30%) rise in serum creatinine. A modest 10%–25% rise in serum creatinine within the first 2 weeks of starting an ACEi/ARB reflects beneficial efferent arteriolar dilation and reduced intraglomerular hypertension; only rises > 30% or hyperkalaemia (> 5.5 mEq/L) warrant evaluation for bilateral renal artery stenosis or volume depletion.

6. Key Takeaways, Related Medicine Monographs & Calculators

Key Study & Practice Takeaways:
  • Target BP < 130/80 mmHg in patients < 65 years with diabetes, CKD, or CAD if well tolerated; < 140/90 mmHg in older frail patients.
  • Monitor serum potassium and serum creatinine within 1–2 weeks of initiating or uptitrating an ACEi, ARB, or Spironolactone.
  • Avoid abrupt withdrawal of Beta-blockers or oral Clonidine to prevent rebound hypertensive crisis.

Related Medicine Monographs

💊 Amlodipine Besylate [3.1] →💊 Telmisartan [3.2] →💊 Losartan Potassium [3.3] →💊 Ramipril [3.5] → ⚖️ Compare Medicines →

Related Clinical Calculators

🧮 Creatinine Clearance (Cockcroft-Gault) →🧮 BMI Calculator (WHO & Indian Consensus) →🧮 Ideal & Adjusted Body Weight →

7. Authoritative Medical & Regulatory References

  1. Indian Pharmacopoeia Commission (IPC) & CDSCO: Indian Pharmacopoeia (IP 2022) & National List of Essential Medicines (NLEM 2022), Ministry of Health and Family Welfare, Government of India (https://ipc.gov.in/ & https://cdsco.gov.in/).
  2. NCBI Bookshelf / National Library of Medicine: StatPearls Pharmacology, Physiology & Clinical Therapeutics Compendia (https://www.ncbi.nlm.nih.gov/books/).
  3. DailyMed (US National Library of Medicine): Official FDA Prescribing Information & Clinical Pharmacology Labelling (US Jurisdiction Reference) (https://dailymed.nlm.nih.gov/dailymed/).
  4. MedlinePlus, NHS Health Information, Cleveland Clinic Health Library & National Institute on Aging (NIA): Structured patient education and clinical communication references (MedlinePlus • NHS • Cleveland Clinic • NIA).